| Literature DB >> 33344075 |
Yunan He1, Shunjie Hu2, Jiaojiao Zhong3, Anran Cheng4, Nianchun Shan5.
Abstract
BACKGROUND: Cervical squamous cancer (CESC) is an intractable gynecological malignancy because of its high mortality rate and difficulty in early diagnosis. Several biomarkers have been found to predict the prognose of CESC using bioinformatics methods, but they still lack clinical effectiveness. Most of the existing bioinformatic studies only focus on the changes of oncogenes but neglect the differences on the protein level and molecular biology validation are rarely conducted.Entities:
Keywords: Bioinformatics; Prognostic biomarker; RFC4; Cervical squamous carcinoma
Year: 2020 PMID: 33344075 PMCID: PMC7718800 DOI: 10.7717/peerj.10386
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Figure 1Identification of 25 common DEGs in the three datasets (GSE39001, GSE7803 and GSE27678) through Venn diagrams software.
Different color meant different datasets. (A) Seven DEGs were up-regulated in the three datasets (logFC > 2). (B). Eighteen DEGs were down-regulated in three datasets (logFC > −2).
25 common DEGs identified from the three datasets.
| Up-regulated | M2M DTL CDKN2A TOP2A NUSAP1 RFC4 PLOD2 |
| Down-regulated | EMP1 IGF1 ALOX12 EDN3 PTGDS KRT1 FOSB GREB1 ESR1 PAMR1 CXCL12 HPGD AR MAL CRNN CRISP3 CFD NDN |
Figure 2GO and KEGG results shows significant signaling pathways of DEGs.
(A) The results of GO analysis for pathways associated with molecular function (MF). (B) The results of GO analysis for pathways associated with cellular component (CC). (C) The results of GO analysis for pathways associated with biological process (BP). (D) The results of KEGG analysis.
GO analysis of different expressed genes in CESC.
| % | ||||||
|---|---|---|---|---|---|---|
| Up-regulated | GOTERM_MF_DIRECT | GO:0005524∼ATP binding | 10 | 21.03 | 2.84E−4 | 0.270953 |
| GOTERM_MF_DIRECT | GO:0003678∼DNA helicase activity | 2 | 4.21 | 0.012333 | 11.169161 | |
| GOTERM_MF_DIRECT | GO:0003688∼DNA replication origin binding | 2 | 4.21 | 0.018445 | 16.278756 | |
| GOTERM_MF_DIRECT | GO:0003682∼chromatin binding | 4 | 8.41 | 0.021525 | 18.752384 | |
| GOTERM_CC_DIRECT | GO:0030496∼midbody | 6 | 12.62 | 2.68E−7 | 2.65E−4 | |
| GOTERM_CC_DIRECT | GO:0005737∼cytoplasm | 14 | 29.44 | 1.50E−4 | 0.147574 | |
| GOTERM_CC_DIRECT | GO:0005876∼spindle microtubule | 3 | 6.31 | 0.001486 | 1.457975 | |
| GOTERM_CC_DIRECT | GO:0005654∼nucleoplasm | 8 | 16.82 | 0.005554 | 5.351061 | |
| GOTERM_CC_DIRECT | GO:0000784∼nuclear chromosome, telomeric region | 3 | 6.31 | 0.063091 | 9.946422 | |
| GOTERM_CC_DIRECT | GO:0072687∼meiotic spindle | 2 | 4.21 | 0.014282 | 13.241928 | |
| GOTERM_CC_DIRECT | GO:0042555∼MCM complex | 2 | 4.21 | 0.014282 | 13.241928 | |
| GOTERM_CC_DIRECT | GO:0005680∼anaphase-promoting complex | 2 | 4.21 | 0.035339 | 29.901598 | |
| GOTERM_CC_DIRECT | GO:0005634∼nucleus | 9 | 18.93 | 0.049470 | 39.406713 | |
| GOTERM_CC_DIRECT | GO:0072686∼mitotic spindle | 2 | 4.21 | 0.054262 | 42.356169 | |
| GOTERM_CC_DIRECT | GO:0005819∼spindle | 2 | 4.21 | 0.062745 | 47.263108 | |
| GOTERM_CC_DIRECT | GO:0000776∼kinetochore | 2 | 4.21 | 0.092682 | 61.726231 | |
| GOTERM_BP_DIRECT | GO:0000910∼cytokinesis | 3 | 6.31 | 9.78E−4 | 1.154575 | |
| GOTERM_BP_DIRECT | GO:0044772∼mitotic cell cycle phase transition | 2 | 4.21 | 0.007770 | 8.844187 | |
| GOTERM_BP_DIRECT | GO:0051988∼regulation of attachment of spindle microtubules to kinetochore | 2 | 4.21 | 0.011633 | 12.969466 | |
| GOTERM_BP_DIRECT | GO:0031145∼anaphase-promoting complex-dependent catabolic process | 2 | 4.21 | 0.013559 | 14.961799 | |
| GOTERM_BP_DIRECT | GO:0006268∼DNA unwinding involved in DNA replication | 2 | 4.21 | 0.015482 | 16.908679 | |
| GOTERM_BP_DIRECT | GO:0007095∼mitotic G2 DNA damage checkpoint | 2 | 4.21 | 0.019316 | 20.670192 | |
| GOTERM_BP_DIRECT | GO:0007076∼mitotic chromosome condensation | 2 | 4.21 | 0.021228 | 22.486821 | |
| GOTERM_BP_DIRECT | GO:0000070∼mitotic sister chromatid segregation | 2 | 4.21 | 0.034511 | 34.093744 | |
| GOTERM_BP_DIRECT | GO:0001578∼microtubule bundle formation | 2 | 4.21 | 0.038274 | 37.079667 | |
| GOTERM_BP_DIRECT | GO:0000281∼mitotic cytokinesis | 2 | 4.21 | 0.040151 | 38.521683 | |
| GOTERM_BP_DIRECT | GO:0006270∼DNA replication initiation | 2 | 4.21 | 0.040151 | 38.521683 | |
| Down-regulated | GOTERM_MF_DIRECT | GO:0005198∼structural molecule activity | 9 | 6.88 | 5.12E−6 | 4.557253 |
| GOTERM_MF_DIRECT | GO:0004252∼serine-type endopeptidase activity | 7 | 5.35 | 1.02E−4 | 0.004512 | |
| GOTERM_MF_DIRECT | GO:0008201∼heparin binding | 6 | 4.59 | 1.73E−4 | 0.187501 | |
| GOTERM_MF_DIRECT | GO:0005496∼steroid binding | 3 | 2.29 | 0.003639 | 3.880030 | |
| GOTERM_MF_DIRECT | GO:0004962∼endothelin receptor activity | 2 | 1.53 | 0.015293 | 11.655613 | |
| GOTERM_MF_DIRECT | GO:0003707∼steroid hormone receptor activity | 3 | 2.29 | 0.022939 | 31.330301 | |
| GOTERM_CC_DIRECT | GO:0005615∼extracellular space | 25 | 19.12 | 7.92E−11 | 7.97E−8 | |
| GOTERM_CC_DIRECT | GO:0070062∼extracellular exosome | 39 | 29.82 | 1.45E−10 | 4.43E−9 | |
| GOTERM_CC_DIRECT | GO:0005576∼extracellular region | 12 | 9.18 | 2.40E−6 | 0.002416 | |
| GOTERM_CC_DIRECT | GO:0001533∼cornified envelope | 5 | 3.82 | 4.01E−5 | 0.040335 | |
| GOTERM_CC_DIRECT | GO:0005578∼proteinaceous extracellular matrix | 7 | 5.35 | 2.35E−4 | 0.236029 | |
| GOTERM_CC_DIRECT | GO:0045095∼keratin filament | 4 | 3.06 | 0.002188 | 2.179044 | |
| GOTERM_CC_DIRECT | GO:0042567∼insulin-like growth factor ternary complex | 2 | 1.53 | 0.023333 | 21.135448 | |
| GOTERM_CC_DIRECT | GO:0031012∼extracellular matrix | 4 | 3.06 | 0.023982 | 21.661062 | |
| GOTERM_CC_DIRECT | GO:0001527∼microfibril | 2 | 1.53 | 0.034797 | 29.965502 | |
| GOTERM_CC_DIRECT | GO:0042581∼specific granule | 2 | 1.53 | 0.062878 | 47.957744 | |
| GOTERM_CC_DIRECT | GO:0016323∼basolateral plasma membrane | 3 | 2.29 | 0.087573 | 60.215342 | |
| GOTERM_BP_DIRECT | GO:0018149∼peptide cross-linking | 5 | 3.82 | 6.99E−4 | 0.098265 | |
| GOTERM_BP_DIRECT | GO:0030216∼keratinocyte differentiation | 5 | 3.82 | 3.21E−4 | 0.451079 | |
| GOTERM_BP_DIRECT | GO:0007565∼female pregnancy | 3 | 2.29 | 0.001635 | 2.274249 | |
| GOTERM_BP_DIRECT | GO:0008284∼positive regulation of cell proliferation | 7 | 5.35 | 0.002416 | 3.344514 | |
| GOTERM_BP_DIRECT | GO:0045840∼positive regulation of mitotic nuclear division | 3 | 2.29 | 0.004434 | 6.057636 | |
| GOTERM_BP_DIRECT | GO:0048146∼positive regulation of fibroblast proliferation | 3 | 2.29 | 0.015351 | 19.550011 | |
| GOTERM_BP_DIRECT | GO:0006955∼immune response | 5 | 3.82 | 0.016764 | 21.157726 | |
| GOTERM_BP_DIRECT | GO:0001558∼regulation of cell growth | 3 | 2.29 | 0.018030 | 22.573586 | |
| GOTERM_BP_DIRECT | GO:0001755∼neural crest cell migration | 3 | 2.29 | 0.0189638 | 23.602523 | |
| GOTERM_BP_DIRECT | GO:0014826∼vein smooth muscle contraction | 2 | 1.53 | 0.022138 | 27.006079 | |
| GOTERM_BP_DIRECT | GO:0001775∼cell activation | 2 | 1.53 | 0.033025 | 37.638886 | |
| GOTERM_BP_DIRECT | GO:0014068∼positive regulation of phosphatidylinositol 3-kinase signaling | 3 | 2.29 | 0.034030 | 38.544070 | |
| GOTERM_BP_DIRECT | GO:0007267∼cell–cell signaling | 3 | 2.29 | 0.042835 | 45.968556 | |
| GOTERM_BP_DIRECT | GO:0021952∼central nervous system projection neuron axonogenesis | 2 | 1.53 | 0.043793 | 46.724165 | |
| GOTERM_BP_DIRECT | GO:0030198∼extracellular matrix organization | 3 | 2.29 | 0.048207 | 50.079668 | |
| GOTERM_BP_DIRECT | GO:0048484∼enteric nervous system development | 2 | 1.53 | 0.049132 | 50.758144 | |
| GOTERM_BP_DIRECT | GO:0043568∼positive regulation of insulin-like growth factor receptor signaling pathway | 2 | 1.53 | 0.049132 | 50.758144 | |
| GOTERM_BP_DIRECT | GO:0005978∼glycogen biosynthetic process | 2 | 1.53 | 0.075392 | 66.786495 | |
| GOTERM_BP_DIRECT | GO:0006885∼regulation of pH | 2 | 1.53 | 0.075392 | 66.786495 | |
| GOTERM_BP_DIRECT | GO:0010596∼negative regulation of endothelial cell migration | 2 | 1.53 | 0.075392 | 66.786595 | |
| GOTERM_BP_DIRECT | GO:0031290∼retinal ganglion cell axon guidance | 2 | 1.53 | 0.080557 | 69.302524 | |
| GOTERM_BP_DIRECT | GO:0010906∼regulation of glucose metabolic process | 2 | 1.53 | 0.090803 | 73.777717 | |
| GOTERM_BP_DIRECT | GO:0048662∼negative regulation of smooth muscle cell proliferation | 2 | 1.53 | 0.095883 | 75.764591 | |
| GOTERM_BP_DIRECT | GO:0048675∼axon extension | 2 | 1.53 | 0.095883 | 75.764591 |
KEGG analysis of DEGs in CESC.
| 04110 | Cell cycle | 13 | 7.76E−6 | PCNA, CDKN2A, BUB1B, CDC7, TTK, SMC1B, CDC20, CCNB1, PTTG1, CDK1, MCM4, MCM5, MCM2 |
| 05200 | Pathways in cancer | 29 | 2.77E−5 | LAMA2, CKS1B, FGF7, EDNRA, EDNRB, RUNX1T1, PDGFRB, PDGFRA, JUP, CDKN2A, MMP1, ITGA2, PTCH1, FN1, IGF2, MITF, FOS, IGF1, WNT16, GNG11, ESR1, AR, CXCL12, GSTA4, CKS2, BIRC5, FGFR2, GSTM5, FGF10 |
| 04512 | ECM-receptor interaction | 9 | 1.36E−4 | TNXB, VWF, LAMA2, ITGA2, ITGA8, SPP1, FN1, HMMR, ITGA9 |
| 05412 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 8 | 2.93E−4 | GJA1, LAMA2, JUP, ITGA2, ITGA8, DSG2, DSC2, ITGA9 |
| 05218 | Melanoma | 8 | 2.93E−4 | PDGFRB, PDGFRA, FGF7, CDKN2A, PDGFD, MITF, IGF1, FGF10 |
| 04151 | PI3K-Akt signaling pathway | 20 | 3.18E−4 | PDGFRB, PDGFRA, TNXB, VWF, LAMA2, ITGA2, IGF2, FN1, IGF1, GNG11, AREG, EREG, GYS2, FGF7, PDGFD, SPP1, ITGA8, FGFR2, FGF10, ITGA9 |
| 04510 | Focal adhesion | 13 | 9.45E−4 | PDGFRB, PDGFRA, TNXB, VWF, LAMA2, ITGA2, FN1, IGF1, MYLK, PDGFD, SPP1, ITGA8, ITGA9 |
| 04270 | Vascular smooth muscle contraction | 10 | 0.001189 | ACTA2, GUCY1A2, PPP1R14A, EDNRA, EDN3, MYH11, MRVI1, AVPR1A, ACTG2, MYLK |
| 03030 | DNA replication | 5 | 0.001491 | PCNA, RFC4, MCM4, MCM5, MCM2 |
| 04114 | Oocyte meiosis | 9 | 0.002920 | CDC20, AR, CCNB1, PTTG1, CDK1, PGR, IGF1, SMC1B,AURKA |
Figure 3Common DEGs PPI network constructed by STRING online database and Module analysis.
(A) Nodes meant proteins; the edges meant the interaction of proteins. (B) Module analysis via Cytoscape MCODE tool (degree cutoff = 2, node score cutoff = 0.2, k-core = 2, and max. Depth = 100).
Figure 4The prognostic information of the 15 core genes.
Three (A, B and C) of 15 genes had a significant better survival rate (P < 0.05) and twelve genes (D–O) had not significant difference in OS (P > 0.05).
The information of prognostic analysis of 15 core DEGs.
| Genes with significant (better) survival ( | TOP2A RFC4 MCM2 |
| Genes without significant survival ( | UBE2C PRC1 NUSAP1 NEK2 MCM5 KIF20A HMMR FANCI ECT2 DTL AURKA ASPM |
Figure 5Expression level of three significantly expressed genes in CESC tissues and normal tissues.
(A) The expression level of TOP2A in CESC tissues and normal tissues. (B) The expression level of MCM2 in CESC tissues and normal tissues. (C) The expression level of RFC4 in CESC tissues and normal tissues. Red color means tumor tissues and grey means normal tissues.
Figure 6The expression of RFC4 on CESC was significantly different compared with para-cancerous tissues from the result of qRT-PCR.
Figure 7Expression levels of RFC4 in different pathological stages of CESC.
The expression of RFC4 in early stage CESC was significantly higher than that in advanced CESC (P = 0.0314).
Figure 8WB analysis of RFC4 protein.
C: CESC tissues, P: para-cancerous tissues. (A) Six pairs CESC tissues WB analysis indicated that except that the results of case 4 are not obvious, the others are consistent with the expected results of high expression of RFC4 in tumor tissues. (B) The grayscale analysis of multiple WB bands shows that the WB tests are reliable.
Figure 9IHC test of CESC.
IHC declared that, in general, the RFC4 protein is highly expressed in tumor tissue sections, and is mainly concentrated in the nucleus, while normal cervical tissue and para-cancerous tissues are underexpressed.